enGene Reports Promising Interim Results for Bladder Cancer Treatment
enGene Therapeutics Inc. has released updated interim results from its Phase 2 LEGEND trial, evaluating detalimogene voraplasmid in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). The trial, which enrolled 125 patients, showed a 54% complete response rate at any time and a 43% rate at six months. The progression to muscle-invasive or advanced disease was low at 3.2%. Detalimogene was generally well tolerated, with most treatment-related adverse events being mild. The company plans to continue engaging with the FDA and the medical community as it evaluates the totality of the data. 
